Introduction: The convergence of bioengineering and artificial intelligence is transforming healthcare through the integration of experimental biology, computational modelling, predictive analytics, and digital health technologies. Nitric oxide (NO), a biological signalling molecule synthesized by nitric oxide synthase (NOS), plays important roles in pancreatic function and glucose homeostasis. However, the contribution of NO to glucose regulation and pancreatic remodelling remains poorly understood. This study investigated the effects of the NOS inhibitors L-NG-nitro-L-arginine methyl ester (L-NAME) and L-NG-monomethyl-L-arginine (L-NMMA) on glucose tolerance, insulin secretion, and pancreatic morphology in rats.
Methods: Thirty-six normal Sprague-Dawley rats were divided into six groups (n=6). Animals received intravenous saline (control), the NO donors S-nitrosocaptopril (CapSNO), S-nitroso-N-acetylpenicillamine (SNAP), and S-nitrosoglutathione (GSNO) at 12.5 mg/kg body weight (BW), or the NOS inhibitors L-NAME and L-NMMA at 30 mg/kg BW. A modified oral glucose tolerance test was performed using a glucose load of 1.75 g/kg BW. Serum insulin concentration was determined, and histological analyses were performed to evaluate pancreatic morphology.
Results and Discussion: NO donor-treated animals (CapSNO, SNAP, and GSNO) exhibited significantly elevated postprandial blood glucose concentration at 90 minutes (p<0.05) and reduced insulin concentration. In contrast, L-NAME and L-NMMA significantly reduced postprandial glucose concentration from 120 minutes onward (p<0.05), with L-NMMA producing the greater hypoglycaemic effect. Histological examination revealed increased pancreatic α-cell populations in NO donor-treated groups. Conversely, NOS inhibitor-treated animals exhibited increased β-cell density, emerging β-cell populations, and marked ductal proliferation, suggesting pancreatic remodelling consistent with β-cell proliferation and possible neogenesis.
Conclusion: NOS inhibition improved glucose tolerance and promoted pancreatic remodelling in normal rats. These findings identify nitric oxide as a potential target for bioengineering approaches aimed at understanding pancreatic adaptation and metabolic regulation. The study provides foundational biochemical, physiological, and histological data for future AI-enabled predictive models and pancreatic digital twin development. Further studies in diabetic models are warranted to validate these findings and explore their translational potential for metabolic disease management.